| 5.19 Data as of May 17 |  +0.03 / +0.58%Today’s Change | 1.57 Today|||52-Week Range 5.45 | +124.68% Year-to-Date |
| Narrower-than-Expected Loss at MannKind - Analyst Blog May 13 / Zacks.com |
| Previous close | 5.16 |
| Today’s open | 5.18 |
| Day’s range | 5.12 - 5.45 |
| Volume | 10,209,096 |
| Average volume (3 months) | 5,401,334 |
| Market cap | $1.5B |
| Dividend yield | -- |
| Earnings growth (last year) | +28.79% |
| Earnings growth (this year) | +51.33% |
| Earnings growth (next 5 years) | +25.00% |
| Revenue growth (last year) | -30.00% |
| P/E ratio | NM |
| Price/Sales | 11,936.43 |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| WXWuXi Pharmatech (Cay... | +0.11 | +0.54% |
| IRWDIronwood Pharmaceuti... | -0.21 | -1.44% |
| AKRXAkorn Inc | +0.05 | +0.35% |
| SNTSSantarus Inc | +0.64 | +3.01% |
| Next reporting date | August 5, 2013 |
| EPS forecast (this quarter) | -$0.14 |
| Annual revenue (last year) | $35.0K |
| Annual profit (last year) | -$169.4M |
| Net profit margin | -483,902.86% |
Sector Health Technology |
Industry Biotechnology |
Chairman & Chief Executive Officer Alfred E. Mann |
President, Chief Operating Officer & Director Hakan S. Edstrom, MBA |
Corporate headquarters Valencia, California |
.
